In summary, we present data demonstrating a role for PKCθ in the induction of suppressive, IL-10-secreting T cells induced in TCR-transgenic mice following chronic antigen administration. This should be considered when contemplating PKCθ as a suitable drug target for inducing immune suppression and graft tolerance.
Introduction
An escalating dose of high-affinity myelin basic protein (MBP)-Ac1-9[4Y] peptide, administered subcutaneously (s.c.) to T cell receptor (TCR) transgenic Tg4 mice, induces peripheral tolerance characterized by the induction of IL-10-secreting CD4 + T cells [1] . These IL-10 + T cells differentiate along the T helper 1 (Th1) pathway, but convert to a regulatory phenotype as part of a negative-feedback loop maintaining peripheral tolerance [2] . Several factors including peptide affinity, dose and solubility and the route of administration used have been shown to play an important role in the successful induction of IL-10 + T cells [3] .
In CD4 + T cells protein kinase C theta (PKCθ) is phosphorylated and activated following ligation of the TCR by peptide-MHC. Active PKCθ is required for initiation of NFκB-a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 dependent transcription therefore naïve CD4 + T cells from PKCθ deficient mice fail to proliferate in response to antigen [4] . PKCθ has also been shown to be specifically required for the differentiation of autoimmunity-associated T helper 17 (Th17) cells [5] and to inhibit the function of FoxP3 + regulatory T cells (Treg) [6] . These observations have led some to suggest that PKCθ represents an attractive drug target for inducing immune suppression in the context of transplant and autoimmunity [7] [8] [9] . However, recent trials of the PKCθ inhibitor sotrastaurin (AEB071), in renal transplant patients, have demonstrated inferior efficacy compared to existing regimes [10, 11] . As peptide affinity, and thus strength-of-signal from the TCR, are crucial in determining efficiency of induction of IL-10-secreting T cells from Th1 effector cells [12, 13] , we hypothesized that altering TCR-mediated signaling by disrupting PKCθ would impact the generation of IL-10 + T cells, and thus the maintenance of peripheral tolerance, following therapeutic peptide administration. We utilized PKCθ-deficient Tg4 mice (Tg4 KO ) to study the role of this signaling pathway on the generation of IL-10-secreting T cells and the induction of a tolerant immune environment following MBP-Ac1-9[4Y] administration.
Materials and methods

Ethical statement
All animal experiments were carried out under the UK Home Office Project Licence number 30/2705 held by David Wraith and the study was approved by the University of Bristol ethical review committee.
Materials
The acetylated N-terminal peptides of myelin basic protein, MBPAc1-9 [4K] (AcASQKRPS QR) and [4Y] (AcASQYRPSQR) were synthesized by GL Biochem Shanghai. In vitro stimulations and assays were performed in complete RPMI (Lonza, supplemented with 5% fetal bovine serum (Biosera), 20mM HEPES, 2mM L-glutamine, 100U/ml penicillin, 100μg/ml streptomycin and 50mM 2-mercaptoethanol). A list of antibodies and details of their use in this study can be found in Table 1 .
Mice and peptide treatments
PKCθ-deficient Tg4 mice were generated by cross breeding Tg4 mice [14] 
Cell isolation
Spleens were disaggregated and red blood cells removed by osmotic lysis. Where indicated, CD4 + T cells were isolated using negative magnetic separation with CD4 + T cell Isolation Kit II (Miltenyi Biotech) or MagniSort™ Mouse CD4 + T cell Enrichment Kit (eBioscience).
Flow cytometry
Splenocytes were stained with Fixable Viability Dye eFluor1 780 (eBioscience) prior to surface immunostaining. Intranuclear staining (for FoxP3 or cMaf) was performed using FoxP3 Staining Buffers (eBioscience). Intracellular cytokine staining was performed following a 3 hour in vitro stimulation in complete RPMI containing 5ng/ml phorbol 12-myristate 13-acetate (PMA) and 500ng/ml ionomycin (both Sigma-Aldrich) in the presence of GolgiStop (BD Biosciences). Cytokine staining was performed using Intracellular Fixation Buffer and Permeabilization Buffer (eBioscience). Data was acquired on an LSR-II or Fortessa X-20 cytometer (BD) and analysed using FlowJo (Treestar). 
RT-PCR
Statistical analysis
Graphs were constructed and data tested for statistical significance in GraphPad Prism version 6.0.
Results
Tg4 KO mice have lower serum IL-10 levels following s.c. [4Y] treatment
We administered a previously-described regimen of escalating s.c. doses of [4Y] peptide to Tg4 WT and Tg4 KO mice ( Fig 1A) and measured the concentration of selected cytokines in peripheral blood serum two hours after each treatment, the point of peak cytokine production following peptide administration [1, 15] . Most strikingly, concentrations of IL-10 were significantly (up to 100-fold) lower in Tg4 KO mice than Tg4 WT ( Fig 1B) . The serum concentration of both IFNγ and IL-2 was equivalent in Tg4 WT and Tg4 KO mice, both showing a peak at the early 80μg doses which was reduced by the final dose, as shown previously [1] (Fig 1C and  1D ). In contrast, serum IL-17A and TNFα concentrations were significantly lower in Tg4 KO mice ( Fig 1E and 1F (Fig 2C-2G ). In contrast, the proportion of IL-10 + CD4 + T cells among Tg4 KO splenocytes was significantly lower than in Tg4 WT (4.1% +/-0.7 verses 12.6% +/-1.0), as was the mRNA expression of il10 in isolated Tg4 KO CD4 + T cells (Fig 2B and 2K ).
We and others have previously identified transcription factors and cell-surface proteins associated with tolerance and specifically with IL-10 + CD4 + T cells [1, 16] PKC theta required for IL-10 + T cell induction ml rhIL-2 (as illustrated in Fig 4A) . The addition of exogenous IL-2 reverses the anergy of the tolerant T cells, promoting IL-10 secretion, and previous studies have shown that restimulation is necessary to observe optimal suppressive effects in vitro [15] . (Fig 5B and 5C ).
Discussion
The aim of this study was to determine if the signaling protein PKCθ plays a role in the induction of suppressive IL-10 + T cells during a tolerance induction protocol of self-antigen administration. IL-10 plays an essential role in the regulation of immune responses and it is therefore important to understand the mechanisms by which it is induced [17] . Furthermore, if PKCθ is to be considered a suitable drug target in immune-mediated diseases [7, 9] , it is essential to understand the implications that inhibiting this kinase may have on all immunoregulatory processes. We demonstrate that PKCθ knock out TCR-transgenic mice fail to upregulate IL-10 following the sequential administration of escalating doses of a high-affinity variant of the relevant cognate antigen, a well-described protocol for the induction of IL-10 + T cells [ fected by PKCθ deficiency. This is consistent with observations that PKCθ is required for the differentiation of Th17 but not Th1 cells [5, 19] . The transcription factor cMaf is essential for IL-10 transcription in macrophages and upregulation of cMaf is associated with IL-10 expression in CD4 + T cells [1, 20] . The mechanism by which Nfil3 is induced in CD4 + T cells remains unknown. In natural killer cells, induction of Nfil3 is dependent on 3 0 -phosphoinositide-dependent kinase 1 (PDK1) [22] , a known substrate of PKCθ [22, 23] [30] . Even in the context of a transgenic TCRαβ a second endogenous α-chain can be selected and variation in this repertoire as a result of PKCθ deficiency may alter the behavior of CD4 + T cells in the periphery. Until recently, PKCθ expression was believed to be restricted to the lymphoid lineage. A recent study has described expression of PKCθ mRNA in macrophages and defined a role for PKCθ in the response of macrophages to infection [31] . This opens the previously unappreciated possibility that PKCθ-deficiency may impact other aspects of the myeloid lineage, innate-derived cytokine production and potentially antigen presentation.
This work presented here demonstrates that PKCθ is required for the efficient induction of IL-10 in effector T cells following administration of an escalating dose of self-antigen to TCRtransgenic mice. This should be considered when contemplating PKCθ as a suitable drug target for promoting immune tolerance and the impact of PKCθ inhibitors, including sotrastaurin, on the induction of IL-10 + CD4 T cells should be investigated. 
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